Autologous HSCT

摘要

Richard Burt and colleagues' study of treatment-related mortality of autologous haemopoietic cell transplantation in progressive autoimmune diseases is promising with an acceptable 5% treatment-related mortality, compared with 10% in the ASTIS trial. However, we believe that some issues need to be further clarified. First, this is a retrospective, non-randomised study done in two centres using two separate groups of patients. Inclusion and exclusion criteria, previous therapies (with alkylating agents or other agents such as bleomycin), substantial comorbidities (such as uncontrolled hypertension), pretransplant performance status, and disease duration have not been included in this manuscript. However, these factors could directly affect the transplant toxicity.